- Home
- BHC vs ADPT Comparison
BHC vs ADPT Comparison
Compare BHC & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHC
- ADPT
- Stock Information
- Founded
- BHC N/A
- ADPT 2009
- Country
- BHC Canada
- ADPT United States
- Employees
- BHC N/A
- ADPT N/A
- Industry
- BHC Biotechnology: Pharmaceutical Preparations
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BHC Health Care
- ADPT Health Care
- Exchange
- BHC Nasdaq
- ADPT Nasdaq
- Market Cap
- BHC 2.2B
- ADPT 2.0B
- IPO Year
- BHC N/A
- ADPT 2019
- Fundamental
- Price
- BHC $6.02
- ADPT $17.26
- Analyst Decision
- BHC Hold
- ADPT Strong Buy
- Analyst Count
- BHC 2
- ADPT 10
- Target Price
- BHC $9.00
- ADPT $14.10
- AVG Volume (30 Days)
- BHC 1.3M
- ADPT 2.0M
- Earning Date
- BHC 10-29-2025
- ADPT 11-05-2025
- Dividend Yield
- BHC N/A
- ADPT N/A
- EPS Growth
- BHC N/A
- ADPT N/A
- EPS
- BHC 0.27
- ADPT N/A
- Revenue
- BHC $9,858,000,000.00
- ADPT $205,216,000.00
- Revenue This Year
- BHC $6.28
- ADPT $32.63
- Revenue Next Year
- BHC $3.76
- ADPT $16.31
- P/E Ratio
- BHC $22.66
- ADPT N/A
- Revenue Growth
- BHC 7.13
- ADPT 21.60
- 52 Week Low
- BHC $4.25
- ADPT $4.27
- 52 Week High
- BHC $9.85
- ADPT $17.62
- Technical
- Relative Strength Index (RSI)
- BHC 32.55
- ADPT 75.70
- Support Level
- BHC $5.90
- ADPT $15.21
- Resistance Level
- BHC $6.19
- ADPT $15.94
- Average True Range (ATR)
- BHC 0.19
- ADPT 0.73
- MACD
- BHC -0.04
- ADPT 0.23
- Stochastic Oscillator
- BHC 13.66
- ADPT 91.98
About BHC Bausch Health Companies Inc.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).